Body mass index and risk of primary liver cancer: a meta-analysis of prospective studies
- PMID: 22956536
- PMCID: PMC3500368
- DOI: 10.1634/theoncologist.2012-0066
Body mass index and risk of primary liver cancer: a meta-analysis of prospective studies
Abstract
Background: Questions remain about the dose-response relationship between body mass index (BMI) and primary liver cancer (PLC) risk, possible confounding by hepatitis virus infection, and differences by gender or geographic location. We performed a meta-analysis of prospective studies to explore these issues.
Methods: We searched PubMed and Embase for studies of BMI and risk of PLC through November 30, 2011. Summary relative risks with their corresponding 95% confidence intervals (CIs) were calculated using a random effects model.
Results: A total of 21 prospective studies (including 17,624 PLC cases) were included in our analysis. The summary relative risk for a 5-unit increment in BMI (in kg/m(2)) was 1.39 (95% CI: 1.25-1.55), with high heterogeneity. These positive results were robust when stratified by sex, geographic location, ascertainment of exposure and outcome, the number of cases, duration of follow-up, sample source, and cofounders. There was evidence of a nonlinear association between BMI and PLC risk, with the most pronounced increase in risk among persons with a BMI >32 kg/m(2). Patients with hepatitis C virus or cirrhosis (but not patients with hepatitis B virus) with excess weight had a higher risk of PLC development than general populations with excess weight.
Conclusion: Excess weight increases PLC risk. For people with HCV infection or cirrhosis, risk increases are greater than for general population.
Conflict of interest statement
Figures
![Figure 1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3500368/bin/onc0111211660001.gif)
![Figure 2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3500368/bin/onc0111211660002.gif)
![Figure 3.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3500368/bin/onc0111211660003.gif)
Similar articles
-
Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies.Eur J Cancer. 2012 Sep;48(14):2137-45. doi: 10.1016/j.ejca.2012.02.063. Epub 2012 Mar 23. Eur J Cancer. 2012. PMID: 22446023 Review.
-
The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans.Am J Gastroenterol. 2001 Aug;96(8):2462-7. doi: 10.1111/j.1572-0241.2001.04054.x. Am J Gastroenterol. 2001. PMID: 11513191
-
Excess body mass index and risk of liver cancer: a nonlinear dose-response meta-analysis of prospective studies.PLoS One. 2012;7(9):e44522. doi: 10.1371/journal.pone.0044522. Epub 2012 Sep 18. PLoS One. 2012. PMID: 23028553 Free PMC article.
-
Effect of type 2 diabetes mellitus on the risk for hepatocellular carcinoma in chronic liver diseases: a meta-analysis of cohort studies.Eur J Cancer Prev. 2015 Mar;24(2):89-99. doi: 10.1097/CEJ.0000000000000038. Eur J Cancer Prev. 2015. PMID: 24809655
-
Body mass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-linear dose-response meta-analysis of prospective studies.Ann Oncol. 2012 Apr;23(4):843-52. doi: 10.1093/annonc/mdr398. Epub 2011 Sep 2. Ann Oncol. 2012. PMID: 21890910 Review.
Cited by
-
Insulin Resistance: The Increased Risk of Cancers.Curr Oncol. 2024 Feb 13;31(2):998-1027. doi: 10.3390/curroncol31020075. Curr Oncol. 2024. PMID: 38392069 Free PMC article. Review.
-
Trends in the burden of most common obesity-related cancers in 16 Southern Africa development community countries, 1990-2019. Findings from the global burden of disease study.Obes Sci Pract. 2023 Nov 21;10(1):e715. doi: 10.1002/osp4.715. eCollection 2024 Feb. Obes Sci Pract. 2023. PMID: 38264007 Free PMC article.
-
NASH/NAFLD-Related Hepatocellular Carcinoma: An Added Burden.Life (Basel). 2023 Dec 23;14(1):25. doi: 10.3390/life14010025. Life (Basel). 2023. PMID: 38255641 Free PMC article.
-
MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges.Cancers (Basel). 2024 Jan 6;16(2):259. doi: 10.3390/cancers16020259. Cancers (Basel). 2024. PMID: 38254750 Free PMC article. Review.
-
A Review of Incidence and Related Risk Factors in the Development of Hepatocellular Carcinoma.Cureus. 2023 Nov 26;15(11):e49429. doi: 10.7759/cureus.49429. eCollection 2023 Nov. Cureus. 2023. PMID: 38149129 Free PMC article. Review.
References
-
- El-Serag HB, Rudolph KL. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–2576. - PubMed
-
- Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–2917. - PubMed
-
- Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–2150. - PubMed
-
- El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med. 2000;160:3227–3230. - PubMed
-
- Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology. 2004;127:S72–78. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical